Mahesh Goel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahesh Goel has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Shraddha Patkar
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
59 shared publications Shraddha Patkar
Tata Memorial Hospital, Mumbai, India
42 shared publications- Vikas Ostwal
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
19 shared publications - Anant Ramaswamy
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
14 shared publications Nitin Shetty
Department of Radiodiagnosis, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai, Maharashtra, India
12 shared publicationsAnant Ramaswamy
Department of Medical Oncology Tata Memorial Hospital Mumbai India
11 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in World Journal of Surgery
Defining the Role of Staging Laparoscopy in the Management of the Gallbladder Cancers: A Single Institution Experience
Introduction: Despite advances in imaging and extensive staging work‐up, occult metastases may still be encountered at laparotomy in patients with apparently resectable gallbladder cancer (GBC), resulting in nontherapeutic surgery. This study evaluates the incremental yield of staging laparoscopy (SL) in detecting radiologically occult metastases in resectable GBC and its role in routine staging. Methods: A prospectively maintained database of patients operated for GBC at a high volume institution was analyzed to calculate the diagnostic yield of SL and the percentage of missed metastases by modern imaging analysis but subsequently diagnosed on SL. In the univariate and multivariate logistic regression, the following binary variables were evaluated to identify predictors of metastasis on SL: (i) NACT (neoadjuvant chemotherapy) receipt: yes versus no; (ii) serum carbohydrate antigen 19–9 (CA19‐9) level: > 1000 u/mL versus ≤ 1000 U/mL; (iii) 18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) scan result: equivocal versus negative (positive results were excluded from this analysis as they would not have proceeded to SL without additional workup); (iv) clinical stage: locally advanced versus early; (v) incidental GBC: yes versus no; (vi) tumor grade: moderate/poorly differentiated versus well differentiated. Results: The SL was incorporated into the diagnostic and management pathway of 330 GBC patients. SL was performed (i) as a staging prior to a planned radical cholecystectomy ( n = 210, 63.6%) and (ii) prior to initiating systemic therapy ( n = 120, 36.4%). The diagnostic yield of SL for detection of metastases over cross‐sectional imaging was 11.5% ( n = 38). Reasons for inoperability on laparotomy were metastatic 16b1 lymph node (LN) ( n = 19, 50%), locally unresectable disease ( n = 15, 39.5%), peritoneal metastasis ( n = 2, 5.3%), and liver metastasis ( n = 2, 5.3%). The reason for locally unresectable disease was right hepatic artery encasement at the porta hepatis. Regression analysis showed that the significant predictors for metastatic disease on SL were equivocal uptake on 18 FDG PET/CT scan ( p = < 0.001) and prior NACT ( p = 0.026). Conclusion: SL provides an incremental detection of radiologically occult metastasis in up to 11.5% patients. The study underscores the benefit of SL and suggests that it should be incorporated in the management of all GBC patients.
- 9 October 2026
- Published by Wiley in World Journal of Surgery
Defining the Role of Staging Laparoscopy in the Management of the Gallbladder Cancers: A Single Institution Experience
Introduction: Despite advances in imaging and extensive staging work‐up, occult metastases may still be encountered at laparotomy in patients with apparently resectable gallbladder cancer (GBC), resulting in nontherapeutic surgery. This study evaluates the incremental yield of staging laparoscopy (SL) in detecting radiologically occult metastases in resectable GBC and its role in routine staging. Methods: A prospectively maintained database of patients operated for GBC at a high volume institution was analyzed to calculate the diagnostic yield of SL and the percentage of missed metastases by modern imaging analysis but subsequently diagnosed on SL. In the univariate and multivariate logistic regression, the following binary variables were evaluated to identify predictors of metastasis on SL: (i) NACT (neoadjuvant chemotherapy) receipt: yes versus no; (ii) serum carbohydrate antigen 19–9 (CA19‐9) level: > 1000 u/mL versus ≤ 1000 U/mL; (iii) 18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) scan result: equivocal versus negative (positive results were excluded from this analysis as they would not have proceeded to SL without additional workup); (iv) clinical stage: locally advanced versus early; (v) incidental GBC: yes versus no; (vi) tumor grade: moderate/poorly differentiated versus well differentiated. Results: The SL was incorporated into the diagnostic and management pathway of 330 GBC patients. SL was performed (i) as a staging prior to a planned radical cholecystectomy ( n = 210, 63.6%) and (ii) prior to initiating systemic therapy ( n = 120, 36.4%). The diagnostic yield of SL for detection of metastases over cross‐sectional imaging was 11.5% ( n = 38). Reasons for inoperability on laparotomy were metastatic 16b1 lymph node (LN) ( n = 19, 50%), locally unresectable disease ( n = 15, 39.5%), peritoneal metastasis ( n = 2, 5.3%), and liver metastasis ( n = 2, 5.3%). The reason for locally unresectable disease was right hepatic artery encasement at the porta hepatis. Regression analysis showed that the significant predictors for metastatic disease on SL were equivocal uptake on 18 FDG PET/CT scan ( p = < 0.001) and prior NACT ( p = 0.026). Conclusion: SL provides an incremental detection of radiologically occult metastasis in up to 11.5% patients. The study underscores the benefit of SL and suggests that it should be incorporated in the management of all GBC patients.
- 10 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 870-878
The Role of Serial Serum Carbohydrate Antigen 19‐9 Surveillance to Detect Recurrences after Curative Resection for Gallbladder Carcinoma
Background: Gallbladder cancer (GBC) is the most common biliary tract malignancy with aggressive biology and poor outcomes. Early detection of recurrence after curative resection is crucial to enable timely systemic therapy. This study evaluates role of Carbohydrate Antigen 19‐9 (CA 19‐9) surveillance in detecting recurrence after radical surgery for GBC. Material and Methods: Retrospective analysis of a prospectively maintained database was conducted at Tata Memorial Hospital, India, between 2010 and 2024. Patients undergoing curative‐intent resection for GBC were included. Postoperative CA 19‐9 trends, including first elevated value and serial rise were analyzed to detect recurrence. Results: A total of 813 patients were analyzed; 327 (40.2%) developed recurrence. Among them, 210 (64.2%) had a postoperative CA19‐9 rise. Fifty‐three patients had CA 19‐9 elevation without clinico‐radiological recurrence. A first raised CA 19‐9 value (> 37 U/mL) predicted recurrence with 64.5% sensitivity, 89.3% specificity (AUC = 0.681). A serial rise in CA 19‐9 value yielded 45.6% sensitivity and 95.3% specificity. The median duration between first raised CA 19‐9 value and radiological detection of recurrence was 5.4 weeks. Conclusions: Serum CA 19‐9 surveillance detects early recurrences in resected GBCs with modest sensitivity and specificity. Serial rise in CA 19‐9 should prompt more detailed investigations to detect recurrence.
- 10 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 870-878
The Role of Serial Serum Carbohydrate Antigen 19‐9 Surveillance to Detect Recurrences after Curative Resection for Gallbladder Carcinoma
Background: Gallbladder cancer (GBC) is the most common biliary tract malignancy with aggressive biology and poor outcomes. Early detection of recurrence after curative resection is crucial to enable timely systemic therapy. This study evaluates role of Carbohydrate Antigen 19‐9 (CA 19‐9) surveillance in detecting recurrence after radical surgery for GBC. Material and Methods: Retrospective analysis of a prospectively maintained database was conducted at Tata Memorial Hospital, India, between 2010 and 2024. Patients undergoing curative‐intent resection for GBC were included. Postoperative CA 19‐9 trends, including first elevated value and serial rise were analyzed to detect recurrence. Results: A total of 813 patients were analyzed; 327 (40.2%) developed recurrence. Among them, 210 (64.2%) had a postoperative CA19‐9 rise. Fifty‐three patients had CA 19‐9 elevation without clinico‐radiological recurrence. A first raised CA 19‐9 value (> 37 U/mL) predicted recurrence with 64.5% sensitivity, 89.3% specificity (AUC = 0.681). A serial rise in CA 19‐9 value yielded 45.6% sensitivity and 95.3% specificity. The median duration between first raised CA 19‐9 value and radiological detection of recurrence was 5.4 weeks. Conclusions: Serum CA 19‐9 surveillance detects early recurrences in resected GBCs with modest sensitivity and specificity. Serial rise in CA 19‐9 should prompt more detailed investigations to detect recurrence.
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500299
ConLymphNet: A Generalizable Region-Constrained Deep Learning Architecture for Precise Abdominal Lymph Node Segmentation Across Cancer Types.
Accurate identification and segmentation of abdominal lymph nodes on computed tomography (CT) is crucial for cancer staging and treatment planning but remains a challenging and time-consuming radiologic task. We developed and validated ConLymphNet, a deep learning-based approach for automated abdominal lymph node segmentation using vertebral landmarks as anatomic reference points to standardize the region of interest. We implemented a novel preprocessing pipeline incorporating vertebral landmark-based region selection followed by a 3D nnUNet segmentation model. The model was trained on 481 contrast-enhanced CT scans from patients with gallbladder cancer (GBC) and validated on external data sets including GBC (n = 54), public lymph node (n = 81), and multicancer data sets (n = 606). Performance was compared with three radiologists of varying experience levels. Interobserver agreement among radiologists and the incremental value of artificial intelligence (AI)-assisted reading were also assessed. To support reproducibility and future research, we also contribute 45 expert-verified lymph node segmentations for cases from public multicancer data sets. ConLymphNet achieved mean Dice coefficients of 0.696 ± 0.179, 0.631 ± 0.187, and 0.639 ± 0.176 and low false-positive rates of 0.78 ± 0.35, 0.81 ± 0.33, 0.93 ± 0.47/volume on internal cross-validation, external GBC, and public lymph node data sets, respectively. Performance varied by lymph node location (P = .0080) and size (P = .0444), with larger nodes yielding better results. The model's detection rate (89.6%) was comparable with experienced residents (89.2%) but with reduced processing time (28.7 ± 12.4s v 165.3 ± 47.8 s). AI assistance improved radiologists' performance significantly, particularly for less experienced readers (detection rate +20.2%, segmentation accuracy +13.0%, P < .001), while reducing false positives by 33.3%. ConLymphNet demonstrates reasonable performance across diverse cancer types and imaging protocols, offering segmentation accuracy comparable with radiologists with substantially faster processing times.
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500299
ConLymphNet: A Generalizable Region-Constrained Deep Learning Architecture for Precise Abdominal Lymph Node Segmentation Across Cancer Types.
Accurate identification and segmentation of abdominal lymph nodes on computed tomography (CT) is crucial for cancer staging and treatment planning but remains a challenging and time-consuming radiologic task. We developed and validated ConLymphNet, a deep learning-based approach for automated abdominal lymph node segmentation using vertebral landmarks as anatomic reference points to standardize the region of interest. We implemented a novel preprocessing pipeline incorporating vertebral landmark-based region selection followed by a 3D nnUNet segmentation model. The model was trained on 481 contrast-enhanced CT scans from patients with gallbladder cancer (GBC) and validated on external data sets including GBC (n = 54), public lymph node (n = 81), and multicancer data sets (n = 606). Performance was compared with three radiologists of varying experience levels. Interobserver agreement among radiologists and the incremental value of artificial intelligence (AI)-assisted reading were also assessed. To support reproducibility and future research, we also contribute 45 expert-verified lymph node segmentations for cases from public multicancer data sets. ConLymphNet achieved mean Dice coefficients of 0.696 ± 0.179, 0.631 ± 0.187, and 0.639 ± 0.176 and low false-positive rates of 0.78 ± 0.35, 0.81 ± 0.33, 0.93 ± 0.47/volume on internal cross-validation, external GBC, and public lymph node data sets, respectively. Performance varied by lymph node location (P = .0080) and size (P = .0444), with larger nodes yielding better results. The model's detection rate (89.6%) was comparable with experienced residents (89.2%) but with reduced processing time (28.7 ± 12.4s v 165.3 ± 47.8 s). AI assistance improved radiologists' performance significantly, particularly for less experienced readers (detection rate +20.2%, segmentation accuracy +13.0%, P < .001), while reducing false positives by 33.3%. ConLymphNet demonstrates reasonable performance across diverse cancer types and imaging protocols, offering segmentation accuracy comparable with radiologists with substantially faster processing times.
- Open Access
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
Occurrence of Biased mTOR Signaling in Hepatocellular Carcinoma
Background: - mTOR signaling promotes cell growth and anabolic processes in all eukaryotes. Hyperactivation of mTOR signaling is associated with various cancers along with hepatocellular carcinoma (HCC). HCC is a highly lethal malignancy with multiple aetiologies such as viral infection, alcohol abuse, and metabolic dysfunction. Therapeutic options for HCC remain limited due to an incomplete understanding of oncogenic drivers and poorly characterized mechanisms of disease progression.Methods: - Various regimens of DEN and CCl4 carcinogen dosage were investigated on C57BL/6J mice to induce HCC. The histological analysis for fibrosis and serum markers for liver function were performed. Molecular analyses of oncogenic drivers were performed in the HCC tissues obtained from mice and HCC patients. The impact of inhibition of mTOR signaling was assessed on HCC progression.Results: - We established a rapid DEN+CCl4 induced (DCI) HCC model in C57BL/6 mice to study disease progression longitudinally. The molecular analysis revealed upregulation of MAPK and downregulation of mTORC1-S6K-S6 signaling in HCC. However, other branches of mTOR such as mTORC1-ULK1, mTORC1-4EBP1, and mTORC2-PKCα were upregulated due to the increased expression. Similar observations were found in tissues derived from HCC patients. Furthermore, inhibition of mTORC1 alone by Rapamycin did not reduce HCC progression but Torin 1 mediated inhibition of both mTORC1 and mTORC2 significantly reduced HCC progression.Conclusions: - We propose this biased mTOR signaling modulates mTOR activity towards specific downstream processes that are crucial for cancer cell growth and targeting both the mTOR complexes has better therapeutic potential in HCC.
- 1 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOccurrence of Biased mTOR Signaling in Hepatocellular Carcinoma
Background: - mTOR signaling promotes cell growth and anabolic processes in all eukaryotes. Hyperactivation of mTOR signaling is associated with various cancers along with hepatocellular carcinoma (HCC). HCC is a highly lethal malignancy with multiple aetiologies such as viral infection, alcohol abuse, and metabolic dysfunction. Therapeutic options for HCC remain limited due to an incomplete understanding of oncogenic drivers and poorly characterized mechanisms of disease progression.Methods: - Various regimens of DEN and CCl4 carcinogen dosage were investigated on C57BL/6J mice to induce HCC. The histological analysis for fibrosis and serum markers for liver function were performed. Molecular analyses of oncogenic drivers were performed in the HCC tissues obtained from mice and HCC patients. The impact of inhibition of mTOR signaling was assessed on HCC progression.Results: - We established a rapid DEN+CCl4 induced (DCI) HCC model in C57BL/6 mice to study disease progression longitudinally. The molecular analysis revealed upregulation of MAPK and downregulation of mTORC1-S6K-S6 signaling in HCC. However, other branches of mTOR such as mTORC1-ULK1, mTORC1-4EBP1, and mTORC2-PKCα were upregulated due to the increased expression. Similar observations were found in tissues derived from HCC patients. Furthermore, inhibition of mTORC1 alone by Rapamycin did not reduce HCC progression but Torin 1 mediated inhibition of both mTORC1 and mTORC2 significantly reduced HCC progression.Conclusions: - We propose this biased mTOR signaling modulates mTOR activity towards specific downstream processes that are crucial for cancer cell growth and targeting both the mTOR complexes has better therapeutic potential in HCC.
- Open Access
- 6 May 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (1) , 116-127
Surgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High‐Volume Sarcoma Centre
Background: Retroperitoneal sarcoma (RPS) is a rare and complex malignancy, requiring specialized multidisciplinary care. While a significant progress has been made in managing a primary RPS, there is a limited literature on the outcomes of recurrent RPS (RecRPS). This study evaluates the oncological outcomes of RecRPS at a leading sarcoma referral center in India. Methods: A retrospective analysis was performed for patients with RecRPS who underwent surgery between January 2011 and December 2024. Clinical outcomes were analyzed using Kaplan‐Meier method and compared using log‐rank test. Extended Cox regression models were used to account for intra‐individual correlation, in cases of multiple recurrence. Prentice, William and Peterson model (PWP) CP model (total time) and PWP Gap time (PWP‐GT) models were employed to estimate predictors of multiple recurrences. Results: Out of 285 patients with primary RPS, 160 (56.1%) underwent surgery for a recurrent disease. The median overall survival (OS) was 137.1 months for the entire cohort and 41.92 months in RecRPS. The median OS of patients with 1st recurrence was 38.97 months. For subsequent recurrences, the median OS were 74.94 months (2nd recurrence), 57.4 months (3rd recurrence) and 54.2 months (4th recurrence), respectively. The various clinicopathological parameter associated with multiple recurrences were R+resection or resection with unknown margins, dedifferentiated liposarcoma and leiomyosarcoma, as histopatholologic subtypes; histologic organ invasion (HOI) of the small bowel and vessels, requirement of adjuvant and neoadjuvant therapy, disease progression on neoadjuvant chemotherapy and grade IIIb and IV complications. Conclusion: While the best chance of cure is at the primary presentation, some patients may experience prolonged disease control even with multiple recurrence, if treated optimally.
- 6 May 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (1) , 116-127
Open AccessSurgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High‐Volume Sarcoma Centre
Background: Retroperitoneal sarcoma (RPS) is a rare and complex malignancy, requiring specialized multidisciplinary care. While a significant progress has been made in managing a primary RPS, there is a limited literature on the outcomes of recurrent RPS (RecRPS). This study evaluates the oncological outcomes of RecRPS at a leading sarcoma referral center in India. Methods: A retrospective analysis was performed for patients with RecRPS who underwent surgery between January 2011 and December 2024. Clinical outcomes were analyzed using Kaplan‐Meier method and compared using log‐rank test. Extended Cox regression models were used to account for intra‐individual correlation, in cases of multiple recurrence. Prentice, William and Peterson model (PWP) CP model (total time) and PWP Gap time (PWP‐GT) models were employed to estimate predictors of multiple recurrences. Results: Out of 285 patients with primary RPS, 160 (56.1%) underwent surgery for a recurrent disease. The median overall survival (OS) was 137.1 months for the entire cohort and 41.92 months in RecRPS. The median OS of patients with 1st recurrence was 38.97 months. For subsequent recurrences, the median OS were 74.94 months (2nd recurrence), 57.4 months (3rd recurrence) and 54.2 months (4th recurrence), respectively. The various clinicopathological parameter associated with multiple recurrences were R+resection or resection with unknown margins, dedifferentiated liposarcoma and leiomyosarcoma, as histopatholologic subtypes; histologic organ invasion (HOI) of the small bowel and vessels, requirement of adjuvant and neoadjuvant therapy, disease progression on neoadjuvant chemotherapy and grade IIIb and IV complications. Conclusion: While the best chance of cure is at the primary presentation, some patients may experience prolonged disease control even with multiple recurrence, if treated optimally.
- 20 April 2026
- Published by Elsevier in Surgical Oncology
- Vol. 66, 102438
Navigating early recurrences in post-hepatectomy hepatocellular carcinoma: Preventive strategies and prognostic indicators
- 20 April 2026
- Published by Elsevier in Surgical Oncology
- Vol. 66, 102438
Navigating early recurrences in post-hepatectomy hepatocellular carcinoma: Preventive strategies and prognostic indicators
- Open Access
- 7 April 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 454-462
Development and Validation of Nomogram Predicting Survival in Resectable Gallbladder Cancer
Background: Gallbladder cancers (GBCs) are aggressive tumors with limited improvement in outcomes over decades. Accurate prediction of survival is crucial for tailored treatment and improved outcomes. Objective: To develop a nomogram predicting overall survival (OS) in resectable GBCs. Methods: A retrospective analysis of 1045 patients of resected gallbladder cancer between January 2010 to December 2022 was done. A predictive nomogram was built and was internally validated. Results: The nomogram included age, original T stage, original N stage, and lympho‐vascular/perineural invasion, CA 19.9, incidental versus non‐incidental GBC, and grade. The Harrell's concordance index for the nomogram was 0.677. The area under the ROC curves for 1‐, 3‐, and 5‐year OS were 72.12, 72.64, and 71.15 respectively. Patients were stratified into low‐risk and high‐risk groups based on a threshold score of 22.48, with significantly different median OS (not reached vs. 31.4 months, p < 0.001). Conclusions: The developed nomogram demonstrates good discriminative capacity and risk stratification in patients undergoing surgery for GBC and may be utilized for better selection and application of adjuvant treatment strategies, potentially improving outcomes.
- 7 April 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 454-462
Open AccessDevelopment and Validation of Nomogram Predicting Survival in Resectable Gallbladder Cancer
Background: Gallbladder cancers (GBCs) are aggressive tumors with limited improvement in outcomes over decades. Accurate prediction of survival is crucial for tailored treatment and improved outcomes. Objective: To develop a nomogram predicting overall survival (OS) in resectable GBCs. Methods: A retrospective analysis of 1045 patients of resected gallbladder cancer between January 2010 to December 2022 was done. A predictive nomogram was built and was internally validated. Results: The nomogram included age, original T stage, original N stage, and lympho‐vascular/perineural invasion, CA 19.9, incidental versus non‐incidental GBC, and grade. The Harrell's concordance index for the nomogram was 0.677. The area under the ROC curves for 1‐, 3‐, and 5‐year OS were 72.12, 72.64, and 71.15 respectively. Patients were stratified into low‐risk and high‐risk groups based on a threshold score of 22.48, with significantly different median OS (not reached vs. 31.4 months, p < 0.001). Conclusions: The developed nomogram demonstrates good discriminative capacity and risk stratification in patients undergoing surgery for GBC and may be utilized for better selection and application of adjuvant treatment strategies, potentially improving outcomes.
- 27 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 734-743
Extranodal Follicular Dendritic Cell Sarcomas and their Oligorecurrences: Lessons Learnt at a Single Tertiary Cancer Referral Centre, India
Background Follicular dendritic cell sarcoma (FDCS) is a rare, aggressive malignant neoplasm usually arising in lymph nodes of the head and neck, but it can also occur at extranodal sites (ENFDCS). Due to its rarity, optimal management is not well defined, underscoring the need for further research. Methods We conducted a retrospective analysis of patients with histologically confirmed ENFDCS treated in the gastrointestinal oncology unit of a tertiary cancer center. Clinical features, treatments, and outcomes were reviewed. Results Fourteen patients (10 males, 4 females; median age 41 years) were included. Primary sites were colon (n = 6), retroperitoneum (n = 3), rectum (n = 2), mesentery (n = 1), liver (n = 1), and pelvis (n = 1). Four tumors (28.6%) were initially misdiagnosed. Final diagnosis was based on morphology and immunohistochemistry for CD21, CD23, and CD35; Epstein–Barr virus testing was not performed. Five patients underwent primary surgery at our center; two patients with metastatic disease at presentation received systemic therapy alone. Among the five primary surgeries, three were preceded by perioperative chemotherapy (n = 1), neoadjuvant chemotherapy (n = 1), or neoadjuvant radiotherapy (n = 1). Seven patients presented with residual or recurrent disease after prior surgery elsewhere; three underwent re-resection following appropriate systemic therapy, and four received only systemic therapy. At a median follow-up of 26 months (range 7–153), median overall survival was not reached, and median disease-free survival was 24 months. Four of five patients primarily operated at our center remained disease free; one recurred at 39 months, was successfully treated with re-resection and systemic therapy, and was alive at 153 months. Of the three patients re-resected at our center, one remained disease free at 17 months, one developed systemic recurrence and eventually received best supportive care at 11 months, and one was disease free until 94 months before being lost to follow-up. Overall, 10 patients were alive, two died of disease progression, and two were lost to follow-up. Conclusion ENFDCS is frequently misdiagnosed; surgery is the cornerstone of treatment, and multimodality therapy for recurrences can yield durable survival. Outcomes appear better when patients are managed at specialized oncologic centers, highlighting the importance of early recognition and timely referral. Graphical Abstract
- 27 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 734-743
Extranodal Follicular Dendritic Cell Sarcomas and their Oligorecurrences: Lessons Learnt at a Single Tertiary Cancer Referral Centre, India
Background Follicular dendritic cell sarcoma (FDCS) is a rare, aggressive malignant neoplasm usually arising in lymph nodes of the head and neck, but it can also occur at extranodal sites (ENFDCS). Due to its rarity, optimal management is not well defined, underscoring the need for further research. Methods We conducted a retrospective analysis of patients with histologically confirmed ENFDCS treated in the gastrointestinal oncology unit of a tertiary cancer center. Clinical features, treatments, and outcomes were reviewed. Results Fourteen patients (10 males, 4 females; median age 41 years) were included. Primary sites were colon (n = 6), retroperitoneum (n = 3), rectum (n = 2), mesentery (n = 1), liver (n = 1), and pelvis (n = 1). Four tumors (28.6%) were initially misdiagnosed. Final diagnosis was based on morphology and immunohistochemistry for CD21, CD23, and CD35; Epstein–Barr virus testing was not performed. Five patients underwent primary surgery at our center; two patients with metastatic disease at presentation received systemic therapy alone. Among the five primary surgeries, three were preceded by perioperative chemotherapy (n = 1), neoadjuvant chemotherapy (n = 1), or neoadjuvant radiotherapy (n = 1). Seven patients presented with residual or recurrent disease after prior surgery elsewhere; three underwent re-resection following appropriate systemic therapy, and four received only systemic therapy. At a median follow-up of 26 months (range 7–153), median overall survival was not reached, and median disease-free survival was 24 months. Four of five patients primarily operated at our center remained disease free; one recurred at 39 months, was successfully treated with re-resection and systemic therapy, and was alive at 153 months. Of the three patients re-resected at our center, one remained disease free at 17 months, one developed systemic recurrence and eventually received best supportive care at 11 months, and one was disease free until 94 months before being lost to follow-up. Overall, 10 patients were alive, two died of disease progression, and two were lost to follow-up. Conclusion ENFDCS is frequently misdiagnosed; surgery is the cornerstone of treatment, and multimodality therapy for recurrences can yield durable survival. Outcomes appear better when patients are managed at specialized oncologic centers, highlighting the importance of early recognition and timely referral. Graphical Abstract
- 11 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 728-733
Splenic Artery Embolization for Refractory Ascites Following Hepatectomy for Hepatocellular Carcinoma
Surgery (Resection/Liver transplant) remains the only curative modality for the treatment of hepatocellular carcinoma (HCC). Post hepatectomy liver failure is the Achilles heel of liver surgery. Management of refractory ascites (RA), following a major resection especially in cirrhotic patients presents a formidable clinical challenge as it is often resistant to conventional treatment modalities. A 72-year gentleman diagnosed with hepatocellular carcinoma in the right lobe of liver with future liver remanent of 45% underwent a right hepatectomy. Postoperatively, despite conservative management with diuretics and albumin he had significantly high drain output. On the 10th day, he underwent proximal splenic artery embolization following which there was a progressive reduction in ascites and drain output. He was discharged in stable condition on the 15th day. Histopathology confirmed moderately differentiated HCC with adjacent steatohepatitis. The patient wass stable and disease free at the 3-month follow-up. Splenic artery embolization offers a safe and minimally invasive technique for management of RA post hepatectomy. Further studies are needed to conclusively establish the safety and utility of this procedure.
- 11 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 728-733
Splenic Artery Embolization for Refractory Ascites Following Hepatectomy for Hepatocellular Carcinoma
Surgery (Resection/Liver transplant) remains the only curative modality for the treatment of hepatocellular carcinoma (HCC). Post hepatectomy liver failure is the Achilles heel of liver surgery. Management of refractory ascites (RA), following a major resection especially in cirrhotic patients presents a formidable clinical challenge as it is often resistant to conventional treatment modalities. A 72-year gentleman diagnosed with hepatocellular carcinoma in the right lobe of liver with future liver remanent of 45% underwent a right hepatectomy. Postoperatively, despite conservative management with diuretics and albumin he had significantly high drain output. On the 10th day, he underwent proximal splenic artery embolization following which there was a progressive reduction in ascites and drain output. He was discharged in stable condition on the 15th day. Histopathology confirmed moderately differentiated HCC with adjacent steatohepatitis. The patient wass stable and disease free at the 3-month follow-up. Splenic artery embolization offers a safe and minimally invasive technique for management of RA post hepatectomy. Further studies are needed to conclusively establish the safety and utility of this procedure.